Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Комбинация азилсартана медоксомила и хлорталидона: новые перспективы в свете исследований SPRINT, HOPE-3 и ACCORDION
Недогода С.В. Комбинация азилсартана медоксомила и хлорталидона: новые перспективы в свете исследований SPRINT, HOPE-3 и ACCORDION. Consilium Medicum. 2016; 18 (5): 8–14. DOI: 10.26442/2075-1753_2016.5.8-14
________________________________________________
Nedogoda S.V. Azilsartan medoxomil/chlorthalidone combination therapy: new prospects in light of SPRINT, HOPE-3 and ACCORDION trials. Consilium Medicum. 2016; 18 (5): 8–14. DOI: 10.26442/2075-1753_2016.5.8-14
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Результаты целого ряда крупных исследований (НОРЕ-3, ACCORDION, SPRINT) убедительно доказывают целесообразность более жесткого контроля артериального давления у пациентов как с умеренным, так и высоким риском развития сердечно-сосудистых осложнений для успешного управления кардиоваскулярным риском, что требует раннего назначения комбинированной антигипертензивной терапии. Необходимы двойные комбинации с максимально выраженным гипотензивным эффектом, благоприятным метаболическим профилем и потенциалом органопротекции, к которым относится фиксированная комбинация азилсартана медоксомил + хлорталидон.
Ключевые слова: артериальная гипертензия, хлорталидон, азилсартана медоксомил.
Ключевые слова: артериальная гипертензия, хлорталидон, азилсартана медоксомил.
________________________________________________
The results of several large trials (НОРЕ3, ACCORDION and SPRINT) proved the usefulness of tight control of blood pressure in patients at moderate and high risk for cardiovascular complications, for successful cardiovascular risk management and the importance of early combination antihypertensive thera- py. Trials showed the need of dual maximum hypotensive effect combinations with favorable metabolic profile and organ protective potential, such as azil- sartan-chlorthalidone fixed combination.
Key words: arterial hypertension, chlorthalidone, azilsartan medoxomil.
Полный текст
Список литературы
1. Yusuf S, Bosch J et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016: p. NEJMoa1600176.
2. Yusuf S, Lonn E et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016: p. NEJMoa1600177.
3. Lonn EM, Bosch J et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374 (21): 2009–20.
4. Wright JT, Williamson JD et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 22 (373): 2103–16.
5. Edarbi (azilsartan medoxomil), prescribing information. Deerfield, Ill.: Takeda; February 2011.
6. FDA approves Edarbi to treat hypertension. February 25, 2011. Available at: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm244722.htm. Accessed May 4, 2011.
7. Sica D, White W et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens 2011; 13: 467–72.
8. White WB, Weber MA et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57 (3): 413–20.
9. Bakris GL, Sica D et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens 2011; 13 (2): 81–8.
10. Rakugi H, Enya K, Sugiura K et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35 (5): 552–8.
11. Bönner G, Bakris G et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27 (8): 479–86.
12. Bönner G, Bakris GL et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: 283.
13. Kusuyama T, Ogata H et al. Effects of Azilsartan Compared to Other Angiotensin Receptor Blockers on Left Ventricular Hypertrophy and the Sympathetic Nervous System in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 2014; 18 (5): 398–403.
14. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68 (9): 1207–25.
15. Kusumoto K, Igata H et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669 (1): 84–93.
16. Iwanami J, Tsukuda K et al. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50 (6): 1099–105.
17. Zhao M, Li Y et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes and Metab 2011; 13 (12): 1123–9.
18. French CJ, Zaman AT et al. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58 (2): 143–8.
19. Cushman WC, Bakris GL et al. Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. Hypertension 2012; 60: 310–8.
20. Cushman WC, Bakris GL et al. Azilsartan medoxomil/chlorthalidone fixed-dose combination lowers BP more than olmesartan/ hydrochlorthalidone fixed-dose combination in stage 2 systolic hypertension. J Hypertens 2011; 29: 118.
21. Dorsch MP, Gillespie BW et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
22. Bakris G, Sica D et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229e1–1229.e10.
23. Kurtz TW. Chlorthalidone: don’t call it “thiazide-like” anymore. Hypertension 2010; 56: 335–7.
24. Carter BL, Ernst ME et al. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4–9.
25. Peterzan MA, Hardy R et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104–9.
26. Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vascular health and risk management. 2006; 4: 401.
2. Yusuf S, Lonn E et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016: p. NEJMoa1600177.
3. Lonn EM, Bosch J et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374 (21): 2009–20.
4. Wright JT, Williamson JD et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 22 (373): 2103–16.
5. Edarbi (azilsartan medoxomil), prescribing information. Deerfield, Ill.: Takeda; February 2011.
6. FDA approves Edarbi to treat hypertension. February 25, 2011. Available at: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm244722.htm. Accessed May 4, 2011.
7. Sica D, White W et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens 2011; 13: 467–72.
8. White WB, Weber MA et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57 (3): 413–20.
9. Bakris GL, Sica D et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens 2011; 13 (2): 81–8.
10. Rakugi H, Enya K, Sugiura K et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35 (5): 552–8.
11. Bönner G, Bakris G et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27 (8): 479–86.
12. Bönner G, Bakris GL et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: 283.
13. Kusuyama T, Ogata H et al. Effects of Azilsartan Compared to Other Angiotensin Receptor Blockers on Left Ventricular Hypertrophy and the Sympathetic Nervous System in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 2014; 18 (5): 398–403.
14. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68 (9): 1207–25.
15. Kusumoto K, Igata H et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669 (1): 84–93.
16. Iwanami J, Tsukuda K et al. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50 (6): 1099–105.
17. Zhao M, Li Y et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes and Metab 2011; 13 (12): 1123–9.
18. French CJ, Zaman AT et al. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58 (2): 143–8.
19. Cushman WC, Bakris GL et al. Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. Hypertension 2012; 60: 310–8.
20. Cushman WC, Bakris GL et al. Azilsartan medoxomil/chlorthalidone fixed-dose combination lowers BP more than olmesartan/ hydrochlorthalidone fixed-dose combination in stage 2 systolic hypertension. J Hypertens 2011; 29: 118.
21. Dorsch MP, Gillespie BW et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
22. Bakris G, Sica D et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229e1–1229.e10.
23. Kurtz TW. Chlorthalidone: don’t call it “thiazide-like” anymore. Hypertension 2010; 56: 335–7.
24. Carter BL, Ernst ME et al. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4–9.
25. Peterzan MA, Hardy R et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104–9.
26. Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vascular health and risk management. 2006; 4: 401.
________________________________________________
1. Yusuf S, Bosch J et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016: p. NEJMoa1600176.
2. Yusuf S, Lonn E et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016: p. NEJMoa1600177.
3. Lonn EM, Bosch J et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374 (21): 2009–20.
4. Wright JT, Williamson JD et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 22 (373): 2103–16.
5. Edarbi (azilsartan medoxomil), prescribing information. Deerfield, Ill.: Takeda; February 2011.
6. FDA approves Edarbi to treat hypertension. February 25, 2011. Available at: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm244722.htm. Accessed May 4, 2011.
7. Sica D, White W et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens 2011; 13: 467–72.
8. White WB, Weber MA et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57 (3): 413–20.
9. Bakris GL, Sica D et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens 2011; 13 (2): 81–8.
10. Rakugi H, Enya K, Sugiura K et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35 (5): 552–8.
11. Bönner G, Bakris G et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27 (8): 479–86.
12. Bönner G, Bakris GL et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: 283.
13. Kusuyama T, Ogata H et al. Effects of Azilsartan Compared to Other Angiotensin Receptor Blockers on Left Ventricular Hypertrophy and the Sympathetic Nervous System in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 2014; 18 (5): 398–403.
14. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68 (9): 1207–25.
15. Kusumoto K, Igata H et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669 (1): 84–93.
16. Iwanami J, Tsukuda K et al. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50 (6): 1099–105.
17. Zhao M, Li Y et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes and Metab 2011; 13 (12): 1123–9.
18. French CJ, Zaman AT et al. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011; 58 (2): 143–8.
19. Cushman WC, Bakris GL et al. Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. Hypertension 2012; 60: 310–8.
20. Cushman WC, Bakris GL et al. Azilsartan medoxomil/chlorthalidone fixed-dose combination lowers BP more than olmesartan/ hydrochlorthalidone fixed-dose combination in stage 2 systolic hypertension. J Hypertens 2011; 29: 118.
21. Dorsch MP, Gillespie BW et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
22. Bakris G, Sica D et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229e1–1229.e10.
23. Kurtz TW. Chlorthalidone: don’t call it “thiazide-like” anymore. Hypertension 2010; 56: 335–7.
24. Carter BL, Ernst ME et al. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4–9.
25. Peterzan MA, Hardy R et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104–9.
26. Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vascular health and risk management. 2006; 4: 401.
Авторы
С.В.Недогода
ГБОУ ВПО Волгоградский государственный медицинский университет Минздрава России. 400131, Россия, Волгоград, пл. Павших Борцов, д. 1
nedogodasv@rambler.ru
ГБОУ ВПО Волгоградский государственный медицинский университет Минздрава России. 400131, Россия, Волгоград, пл. Павших Борцов, д. 1
nedogodasv@rambler.ru
________________________________________________
S.V.Nedogoda
Volgograd State Medical University of Ministry of Health of the Russian Federation. 400131, Russian Federation, Volgograd, pl. Pavshikh Bortsov, d. 1
nedogodasv@rambler.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.